Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-E7
- Development stage
- Unknown
- Lead developer
- Pasteur Institute of Iran
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-E7 is an experimental oral live bacterial vaccine developed for the prevention and treatment of human papillomavirus type 16 (HPV-16) associated malignancies, including cervical cancer. The vaccine utilizes a genetically modified, food-grade strain of *Lactococcus lactis* (NZ9000) as a delivery vehicle for the HPV-16 E7 oncoprotein. The E7 gene is carried on the pNZ8123 plasmid vector and its expression is regulated by a nisin-inducible promoter (PnisA) and the SPusp45 secretion signal, allowing for the extracellular production of the antigen. Upon oral administration, the recombinant bacteria interact with the mucosal immune system in the gut to stimulate both humoral and cell-mediated immune responses against the E7 tumor-specific antigen. This candidate has progressed to Phase I clinical testing in Iran, where it has shown a favorable safety profile.
- Other names
- Lactococcus lactis NZ9000 pNZ8123-HPV16-E7recombinant L. lactis expressing HPV-16 E7HPV-16 E7 oral vaccineHPV16 E7 oral vaccineHPV 16 E7 oral vaccine
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-E7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-E7.